United States

Advised Derma Sciences, Inc., a tissue regeneration company focused on advanced wound and burn care, on the acquisition of a proprietary regenerative medicine products company BioD, LLC and a concurrent private placement.

Advised New Enterprise Stone & Lime Co., Inc. on $555 million of secured financings, including a new $450 million senior secured term loan and substantial amendments to its existing $105 million ABL revolver

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to an authorized generic version of Adderall XR

Served as independent financial advisor to the Board of Directors of Gannett in connection with its acquisition of ReachLocal

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 2 generic drug products to Zydus Cadila

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 5 generic injectable drug products  to Sagent Pharmaceuticals, Inc. 

Advised QLT Inc. on its merger with Aegerion Pharmaceuticals and concurrent equity raise to create a rare disease-focused global biopharmaceutical organization

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories